Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 38589271 · doi:10.1016/j.pcad.2024.04.001
What was done
Systematic review and meta-analysis of randomized controlled trials searched across PubMed, EMBASE, and ClinicalTrials.gov from inception through September 30, 2023. The authors evaluated cardiovascular disease outcomes and mortality in hypogonadal men receiving testosterone replacement therapy compared to placebo.
What was found
Across 30 randomized trials with 11,502 patients (mean age 61.61 to 61.82 years), testosterone replacement therapy showed no significant difference compared to placebo for any cardiovascular disease events (OR 1.12, 95% CI 0.77-1.62, P = 0.55), stroke (OR 1.01, 95% CI 0.68-1.51, P = 0.94), myocardial infarction (OR 1.05, 95% CI 0.76-1.45, P = 0.77), all-cause mortality (OR 0.94, 95% CI 0.76-1.17, P = 0.57), or cardiovascular disease mortality (OR 0.87, 95% CI 0.65-1.15, P = 0.31).
Why it matters
This meta-analysis provides pooled randomized trial evidence demonstrating that testosterone replacement therapy does not increase cardiovascular events or mortality in men with hypogonadism.
Limits
The abstract does not provide details on treatment duration, testosterone formulation or dosage, participant baseline cardiovascular risk, or statistical heterogeneity across trials.
Cited by
- supports There is no scientific evidence that testosterone therapy extends lifespan or promotes longevity.